Business
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions BASKING RIDGE, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced encouraging preliminary data from the pancreatic du
About this update from Lisata Therapeutics, Inc.
[{"type":"image","alt":"Lisata Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Lisata Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/67f4449bf2ef469a75e1732240c6e363"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y4XbqVAm8oIdeBK9.mjRkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67f4449bf2ef469a75e1732240c6e363","width":300,"height":84}},"lazy":false},{"type":"text","content":"Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions","length":163,"tagName":"p"},{"type":"text","content":"BASKING RIDGE, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced encouraging preliminary data from the pancreatic ductal adenocarcinoma (“PDAC”) cohort of the Phase 1/2a CENDIFOX trial (NCT05121038). The investigator-initiated trial, led by Anup Kasi, M.D., M.P.H., at The University of Kansas (“KU”) Cancer Center, is evaluating Lisata's proprietary investigational iRGD cyclic peptide product candidate, certepetide, in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers.","length":754,"tagName":"p"},{"type":"text","content":"The preliminary data will be presented in poster A070, titled “CENDIFOX: Phase I/II Trial of CEND-1 (LSTA1, certepetide) with Neoadjuvant mFOLFIRINOX in Resectable and Borderline Resectable PDAC,” at the American Association for Cancer Research (“AACR”) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions on September 29, 2025, from 4:30 p.m. - 7:00 p.m. in Boston, Massachusetts. The poster presentation will highlight findings from patients with resectable and borderline resectable PDAC, with the full abstract available on the AACR website.","length":621,"tagName":"p"},{"type":"text","content":"“The preliminary trial data has been very promising, and we’re excited to share these findings with the broader oncology com...